1. No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate‐to‐severe plaque psoriasis. (1st February 2018) Authors: Strober, B.E.; Langley, R.G.B.; Menter, A.; Magid, M.; Porter, B.; Fox, T.; Safi, J.; Papavassilis, C. Journal: British journal of dermatology Issue: Volume 178:Number 2(2018) Page Start: e105 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. No elevated risk for depression, anxiety or suicidality with secukinumab in a pooled analysis of data from 10 clinical studies in moderate‐to‐severe plaque psoriasis. (22nd December 2017) Authors: Strober, B.E.; Langley, R.G.B.; Menter, A.; Magid, M.; Porter, B.; Fox, T.; Safi, J.; Papavassilis, C. Journal: British journal of dermatology Issue: Volume 178:Number 2(2018) Page Start: e105 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Reply to: "Letter to the Editor: Claims about the effects of botulinum toxin on depression should raise some eyebrows". (August 2021) Authors: Finzi, E.; Schulze, J.; Neumann, I.; Magid, M.; Sinke, C.; Wollmer, M.A.; Krüger, T.H.C. Journal: Journal of psychiatric research Issue: Volume 140(2021) Page Start: 553 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗